1. Home
  2. GCV vs CGTX Comparison

GCV vs CGTX Comparison

Compare GCV & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Convertible and Income Securities Fund Inc. (The)

GCV

Gabelli Convertible and Income Securities Fund Inc. (The)

HOLD

Current Price

$3.98

Market Cap

77.8M

Sector

Finance

ML Signal

HOLD

CGTX

Cognition Therapeutics Inc.

SELL

Current Price

$0.73

Market Cap

79.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
GCV
CGTX
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.8M
79.6M
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
GCV
CGTX
Price
$3.98
$0.73
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $3.33
AVG Volume (30 Days)
65.8K
★ 472.3K
Earning Date
01-01-0001
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 62.79
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.82
$0.55
52 Week High
$4.80
$1.83

Technical Indicators

Market Signals
Indicator
GCV
CGTX
Relative Strength Index (RSI) 37.43 35.59
Support Level $3.82 $0.55
Resistance Level $4.57 $1.18
Average True Range (ATR) 0.09 0.06
MACD 0.01 0.00
Stochastic Oscillator 32.05 24.66

Price Performance

Historical Comparison
GCV
CGTX

About GCV Gabelli Convertible and Income Securities Fund Inc. (The)

GABELLI CONVERTIBLE & INCOME SECURITIES FUND INC is a diversified closed-end management investment company. Its investment objective is to seek a high level of total return through a combination of current income and capital appreciation by investing in convertible securities. The company invests in various portfolios such as Health Care, Financial Services, Real Estate Investment Trust, Energy and Utilities, Telecommunications, Food and Beverage, Aerospace and Automotive, and others. All the operation of the group is operated through the regions of the United States.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: